ClinicalTrials.gg
CompletedNCT01568112Updated Jun 13, 2016Results posted

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

A Phase 3 interventional study of BG00012 (dimethyl fumarate) and BG00012 placebo in Healthy, sponsored by Biogen. Completed at 1 site in United States. Open to participants aged 25 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-13.

Sponsored by Biogen · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
173
Allocation
Randomized
Ages
25 Years to 55 Years
Sex
All
01

Study summary

The primary objective of the study is to evaluate whether premedication with 325 mg microcoated aspirin (ASA) tablet or a slow-titration dosing schedule of BG00012 reduces the incidence and severity of flushing and GI events following oral administration of BG00012 dosed at 240 mg twice a day (BID) in healthy volunteers. The secondary objective of this study is to evaluate the safety and tolerability of BG00012 when administered orally as a 240 mg BID dose regimen with and without 325 mg ASA premedication or following a slow-titration dosing schedule in healthy volunteers.

02

Conditions studied

  • Healthy

Keywords

  • BG00012
  • gastrointestinal events
  • flushing events
  • dose titration
  • pre-medication
  • aspirin
03

In context

Lead sponsor

Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.

Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Must give written and any authorizations required by local law
  • Must have a (BMI) of between 18.0 to 34.0 kg/m\^2,inclusive.
  • Ability to complete the tolerability scales by accurately using the hand-held subject reporting device
  • Subjects of must be willing to practice effective

Key Exclusion Criteria:

  • History of diseases
  • History of severe allergic or anaphylactic reactions
  • Intolerance to aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Diarrhea, constipation, abdominal pain, flushing or nausea within 28 days prior to Day 1

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
173 participants (actual)

Study arms

  • Experimental
    BG00012

    Participants received BG00012 for 8 weeks (120 mg BID during the first week and 240 mg BID during the subsequent 7 weeks) and premedication with ASA placebo during the first 4 weeks.

    Drug: BG00012 (dimethyl fumarate) · Drug: BG00012 placebo · Drug: ASA placebo

  • Placebo comparator
    Placebo

    Participants received BG00012 placebo for 8 weeks and premedication with ASA placebo during the first 4 weeks.

    Drug: BG00012 placebo · Drug: ASA placebo

  • Experimental
    BG00012 + ASA

    Participants received BG00012 for 8 weeks (120 mg BID during the first week and 240 mg BID during the subsequent 7 weeks) and premedication with ASA during the first 4 weeks.

    Drug: BG00012 (dimethyl fumarate) · Drug: BG00012 placebo · Drug: ASA

  • Experimental
    BG00012 Slow Titration

    Participants received BG00012 for 8 weeks (120 mg once daily \[QD\] during Week 1, 120 mg BID during Week 2, 240 mg AM/120mg PM during Week 3, and 240 mg BID during Week 4, and 240 mg BID during Weeks 5 to 8) and premedication with ASA placebo during the first 4 weeks.

    Drug: BG00012 (dimethyl fumarate) · Drug: BG00012 placebo · Drug: ASA placebo

Interventions

  • Each capsule contains 120 mg dimethyl fumarate (DMF). Fast titration involves taking one 120 mg capsule in the morning and one in the evening (240 mg daily) for one week, and then escalating to a dose of 480 mg daily (two capsules morning and evening) for the remainder of the study.Slow titration expands the dose escalation time to 4 weeks.

    Also known as: BG-12, oral fumarate, DMF

  • DrugBG00012 placebo

    Placebo matching BG00012

  • DrugASA

    325 mg microcoated aspirin (ASA)

    Also known as: acetylsalicylic acid, aspirin

  • DrugASA placebo

    Placebo matching aspirin

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Reporting Overall Flushing Events During the Overall Treatment Period, as Assessed by the Modified Flushing Severity Scale (MFSS)

    Participant-reported flushing side effect events during the treatment period recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects).

    Time frame: Day 1 to Week 8

  2. Percentage of Participants Reporting Overall Flushing Events During Weeks 1 to 4 (Combined), as Assessed by MFSS

    Participant-reported flushing side effect events during Weeks 1 to 4 recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects).

    Time frame: Week 1 to Week 4

  3. Percentage of Participants Reporting Overall Flushing Events During Weeks 5 to 8 (Combined), as Assessed by MFSS

    Participant-reported flushing side effect events during Weeks 1 to 4 recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects).

    Time frame: Week 5 to Week 8

  4. Worst Severity Scores of Overall Flushing During Weeks 1 to 4 of Treatment (Combined), as Assessed by MFSS

    Worst severity of participant-reported flushing events during Weeks 1-4 of treatment combined, recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects).

    Time frame: Day 1 to Week 4

  5. Worst Severity Scores of Overall Flushing During Weeks 5 to 8 of Treatment (Combined), as Assessed by MFSS

    Worst severity of participant-reported flushing events during Weeks 1-4 of treatment combined, recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin.This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects).

    Time frame: Week 5 to Week 8

  6. Percentage of Participants Reporting Overall Flushing Events During the Overall Treatment Period, as Assessed by the Modified Global Flushing Severity Scale (MGFSS)

    Participant-reported flushing events during the overall treatment period, recorded on the hand-held participant reporting device (eDiary) as assessed by MGFSS. The MGFSS measures the side effects related to flushing during the past 24 hours. Flushing means redness, warmth, tingling or itching of the skin. Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). Day 1 data are not included in the analysis because MGFSS question refers to events reported in the 24 hours after the first dose on Day 1.

    Time frame: Day 2 to Week 8

  7. Percentage of Participants Reporting Overall Flushing Events During Weeks 1 to 4 of Treatment (Combined), as Assessed by MGFSS

    Participant-reported flushing events during Weeks 1 to 4 of treatment (combined), recorded on the hand-held participant reporting device (eDiary) as assessed by MGFSS. The MGFSS measures the side effects related to flushing during the past 24 hours. Flushing means redness, warmth, tingling or itching of the skin. Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). Day 1 data are not included in the analysis because MGFSS question refers to events reported in the 24 hours after the first dose on Day 1.

    Time frame: Day 2 to Week 4

  8. Percentage of Participants Reporting Overall Flushing Events During Weeks 5 to 8 of Treatment (Combined), as Assessed by MGFSS

    Participant-reported flushing events during Weeks 5 to 8 of treatment (combined), recorded on the hand-held participant reporting device (eDiary) as assessed by MGFSS. The MGFSS measures the side effects related to flushing during the past 24 hours. Flushing means redness, warmth, tingling or itching of the skin. Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). Day 1 data are not included in the analysis because MGFSS question refers to last 24 hours flushing score.

    Time frame: Week 5 to Week 8

  9. Percentage of Participants Reporting Gastrointestinal (GI) Events During the Overall Treatment Period, as Assessed by the Modified Acute Gastrointestinal Scale (MAGISS)

    The MAGISS is a participant-reported questionnaire about side effects of the gastrointestinal system following drug administration, and is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. A participant was considered having overall GI side effect if he/she had a score of \>=1 for at least one of the GI side effects including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating and flatulence.

    Time frame: Day 1 to Week 8

  10. Percentage of Participants Reporting GI Events During Weeks 1 to 4 of Treatment (Combined), as Assessed by MAGISS

    The MAGISS is a participant-reported questionnaire about side effects of the gastrointestinal system following drug administration, and is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. A participant was considered having overall GI side effect if he/she had a score of \>=1 for at least one of the GI side effects including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating and flatulence.

    Time frame: Day 1 to Week 4

  11. Percentage of Participants Reporting GI Events During Weeks 5 to 8 of Treatment (Combined), as Assessed by MAGISS

    The MAGISS is a participant-reported questionnaire about side effects of the gastrointestinal system following drug administration, and is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. A participant was considered having overall GI side effect if he/she had a score of \>=1 for at least one of the GI side effects including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating and flatulence.

    Time frame: Week 5 to Week 8

  12. Worst Severity Scores of Acute GI Events During Weeks 1 to 4 of Treatment (Combined), as Assessed by MAGISS

    Severity of GI-related events using the MAGISS to measure GI symptoms (nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, flatulence), based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms.

    Time frame: Day 1 to Week 4

  13. Worst Severity Scores of Acute GI Events During Weeks 5 to 8 of Treatment (Combined), as Assessed by MAGISS

    Severity of GI-related events using the MAGISS to measure GI symptoms (nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, flatulence), based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms.

    Time frame: Week 5 to Week 8

  14. Percentage of Participants Reporting GI Events During the Overall Treatment Period, as Assessed by the Modified Overall Gastrointestinal Symptom Scale (MOGISS)

    The MOGISS is a questionnaire about overall side effects related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. Participants were to answer the questions at the same time each day, before the morning drug administration.

    Time frame: Day 1 to Week 8

  15. Percentage of Participants Reporting GI Events During Weeks 1 to 4 (Combined), as Assessed by the Modified Overall Gastrointestinal Symptom Scale (MOGISS)

    The MOGISS is a questionnaire about overall side effects related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. Participants were to answer the questions at the same time each day, before the morning drug administration.

    Time frame: Week 1 to Week 4

  16. Percentage of Participants Reporting GI Events During Weeks 5 to 8 (Combined), as Assessed by the Modified Overall Gastrointestinal Symptom Scale (MOGISS)

    The MOGISS is a questionnaire about overall side effects related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. Participants were to answer the questions at the same time each day, before the morning drug administration.

    Time frame: Week 5 to Week 8

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious AEs (SAEs)

    AE: any untoward medical occurrence that does not necessarily have a causal relationship with treatment. SAE: any untoward medical occurrence that at any dose: results in death; in the view of the Investigator, places the subject at immediate risk of death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, may jeopardize the subject or may require intervention to prevent one of the other outcomes. An AE was considered treatment-emergent if it occurred after the start of study treatment or was present prior to the start of study treatment but subsequently worsened.

    Time frame: Day 1 up to end of Safety Follow-up (9 weeks)

  2. Clinical Laboratory Shifts From Baseline in Reported Values: Hematology

    Number of participants with clinical laboratory shifts from baseline in hematology values. Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. abs=absolute

    Time frame: Day 1 to Week 8

  3. Clinical Laboratory Shifts From Baseline in Reported Values: Blood Chemistry

    Number of participants with clinical laboratory shifts from baseline in blood chemistry values. Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. ALP=alkaline phosphatase, ALT=alanine aminotransferase, AST=aspartate aminotransferase, GGT=gamma-glutamyl transferase, LDH=lactate dehydrogenase, BUN=blood urea nitrogen.

    Time frame: Day 1 to Week 8

  4. Clinical Laboratory Shifts From Baseline in Reported Values: Urinalysis

    Number of participants with clinical laboratory shifts from baseline in urinalysis values.Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. Shift to positive includes negative to positive and unknown to positive. RBC=red blood cells, WBC=white blood cells.

    Time frame: Day 1 to Week 8

  5. Number of Participants With Abnormalities in Vital Signs

    ↑=increase; ↓=decrease; BL=baseline; bpm=beats per minute; SBP=systolic blood pressure; DBP=diastolic blood pressure; b/m=breaths per minute

    Time frame: Day 1 to Week 8

  6. Number of Participants With Shifts From Baseline in Electrocardiogram (ECG) Results

    Shift to 'abnormal, not adverse event' includes unknown or normal to 'abnormal, not adverse event.' Shift to 'abnormal, adverse event' includes unknown or normal to 'abnormal, adverse event.'

    Time frame: Day 1 to Week 8

  7. Duration of Flushing Events During the Overall Treatment Period, Based on MFSS

    For participants with more than 1 flushing episode during a visit interval, the average duration for the visit interval was used. The average duration is calculated as: the total duration of all flushing episodes / the total number of flushing episodes.

    Time frame: Day 1 to Week 8

  8. Duration of Flushing Events During the Weeks 1 to 4 (Combined), Based on MFSS

    For participants with more than 1 flushing episode during a visit interval, the average duration for the visit interval was used. The average duration is calculated as: the total duration of all flushing episodes / the total number of flushing episodes.

    Time frame: Week 1 to Week 4

  9. Duration of Flushing Events During the Weeks 5 to 8 (Combined), Based on MFSS

    For participants with more than 1 flushing episode during a visit interval, the average duration for the visit interval was used. The average duration is calculated as: the total duration of all flushing episodes / the total number of flushing episodes.

    Time frame: Week 5 to Week 8

  10. Duration of Acute GI Episodes During the Overall Treatment Period, Based on MAGISS

    Duration is calculated as follows: \[(GI side effect) end date/time - (GI side effect) start date/time\]/3600. For GI side effects with no end date, the end date is imputed using the last diary date/time. For subjects with more than 1 GI episode during a visit interval, the average duration for the study visit interval is used. The average duration is calculated as the total duration of the GI side effect / the total number of GI side effects.

    Time frame: Day 1 to Week 8

  11. Duration of Acute GI Episodes During Weeks 1 to 4 (Combined), Based on MAGISS

    Duration is calculated as follows: \[(GI side effect) end date/time - (GI side effect) start date/time\]/3600. For GI side effects with no end date, the end date is imputed using the last diary date/time. For subjects with more than 1 GI episode during a visit interval, the average duration for the study visit interval is used. The average duration is calculated as the total duration of the GI side effect / the total number of GI side effects.

    Time frame: Week 1 to Week 4

  12. Duration of Acute GI Episodes During Weeks 5 to 8 (Combined), Based on MAGISS

    Duration is calculated as follows: \[(GI side effect) end date/time - (GI side effect) start date/time\]/3600. For GI side effects with no end date, the end date is imputed using the last diary date/time. For subjects with more than 1 GI episode during a visit interval, the average duration for the study visit interval is used. The average duration is calculated as the total duration of the GI side effect / the total number of GI side effects.

    Time frame: Week 5 to Week 8

07

Results

Posted Jun 13, 2016

Participant flow

Participant flow — Overall Study
MilestonePlaceboBG00012BG00012 + ASABG00012 Slow Titration
Started44444342
Completed39363630
Not completed58712
Withdrew: Randomized but not treated0100
Withdrew: Withdrew due to adverse event2463
Withdrew: Lost to follow-up0001
Withdrew: Withdrawal by subject2307
Withdrew: Withdrawal by physician1011

Outcome measures

PrimaryPercentage of Participants Reporting Overall Flushing Events During the Overall Treatment Period, as Assessed by the Modified Flushing Severity Scale (MFSS)

Participant-reported flushing side effect events during the treatment period recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects).

Time frame:
Day 1 to Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Overall Flushing Events During the Overall Treatment Period, as Assessed by the Modified Flushing Severity Scale (MFSS)
percentage of participantsPlaceboBG00012BG00012 + ASABG00012 Slow Titration
Overall flushing events41918198
Overall redness events27867790
Overall warmth events41938498
Overall tingling events23886786
Overall itching events20867298
Statistical analysis
  • BG00012 vs BG00012 + ASA · Difference in percentage: -9 · 95% CI -30.8 to 12.9Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: 7 · 95% CI -14.1 to 27.8Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Difference in percentage: -9 · 95% CI -30.8 to 12.9Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: 4 · 95% CI -16.4 to 25.5Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Difference in percentage: -21 · 95% CI -41.7 to 1.3Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: -3 · 95% CI -23.3 to 18.7Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Difference in percentage: -14 · 95% CI -35.2 to 8.3Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: 12 · 95% CI -9.5 to 32.2Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Difference in percentage: -9 · 95% CI -30.8 to 12.9Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: 5 · 95% CI -16.4 to 25.5Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
PrimaryPercentage of Participants Reporting Overall Flushing Events During Weeks 1 to 4 (Combined), as Assessed by MFSS

Participant-reported flushing side effect events during Weeks 1 to 4 recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects).

Time frame:
Week 1 to Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Overall Flushing Events During Weeks 1 to 4 (Combined), as Assessed by MFSS
percentage of participantsPlaceboBG00012BG00012 + ASABG00012 Slow Titration
Overall flushing events41867298
Overall redness events25816388
Overall warmth events41886795
Overall tingling events23845183
Overall itching events16775695
Statistical analysis
  • BG00012 vs BG00012 + ASA · Difference in percentage: -14 · 95% CI -35.2 to 8.3Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: 12 · 95% CI -9.5 to 32.2Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Difference in percentage: -19 · 95% CI -39.6 to 3.7Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: 7 · 95% CI -14.1 to 27.8Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Difference in percentage: -21 · 95% CI -41.7 to 1.3Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: 7 · 95% CI -14.1 to 27.8Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Difference in percentage: -33 · 95% CI -52.2 to -10.6Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: -0 · 95% CI -21.0 to 21.0Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Difference in percentage: -21 · 95% CI -41.7 to 1.3Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: 18 · 95% CI -2.4 to 38.8Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
PrimaryPercentage of Participants Reporting Overall Flushing Events During Weeks 5 to 8 (Combined), as Assessed by MFSS

Participant-reported flushing side effect events during Weeks 1 to 4 recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects).

Time frame:
Week 5 to Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Overall Flushing Events During Weeks 5 to 8 (Combined), as Assessed by MFSS
percentage of participantsPlaceboBG00012BG00012 + ASABG00012 Slow Titration
Overall flushing events24867285
Overall redness events15786479
Overall warmth events17867582
Overall tingling events15816470
Overall itching events22785861
Statistical analysis
  • BG00012 vs BG00012 + ASA · Difference in percentage: -14 · 95% CI -35.6 to 9.2Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: -2 · 95% CI -24.7 to 21.7Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Difference in percentage: -14 · 95% CI -35.6 to 9.2Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: 0 · 95% CI -22.9 to 23.7Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Difference in percentage: -11 · 95% CI -33.0 to 11.9Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: -5 · 95% CI -27.5 to 18.8Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Difference in percentage: -17 · 95% CI -38.1 to 6.5Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: -11 · 95% CI -34.2 to 12.2Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Difference in percentage: -20 · 95% CI -40.6 to 3.8Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: -18 · 95% CI -40.2 to 5.5Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
PrimaryWorst Severity Scores of Overall Flushing During Weeks 1 to 4 of Treatment (Combined), as Assessed by MFSS

Worst severity of participant-reported flushing events during Weeks 1-4 of treatment combined, recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects).

Time frame:
Day 1 to Week 4
Reported as:
Mean · units on a scale
Worst Severity Scores of Overall Flushing During Weeks 1 to 4 of Treatment (Combined), as Assessed by MFSS
units on a scalePlaceboBG00012BG00012 + ASABG00012 Slow Titration
Overall flushing1.2 ± 1.704.4 ± 2.682.4 ± 2.265.6 ± 2.24
Redness0.7 ± 1.333.8 ± 2.761.6 ± 1.755.1 ± 2.93
Warmth1.2 ± 1.764.0 ± 2.552.3 ± 2.175.2 ± 2.37
Tingling0.5 ± 1.003.4 ± 2.211.6 ± 2.134.0 ± 2.62
Itching0.5 ± 1.213.2 ± 2.451.3 ± 1.724.3 ± 2.10
Statistical analysis
  • BG00012 vs BG00012 + ASA · Mean difference: -1.9 · 95% CI -3.0 to -0.9Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference: 1.2 · 95% CI 0.2 to 2.3Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference: -2.2 · 95% CI -3.2 to -1.2Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 + ASA vs BG00012 Slow Titration · Mean difference: 1.3 · 95% CI 0.1 to 2.5Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference: -1.7 · 95% CI -2.8 to -0.7Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 + ASA vs BG00012 Slow Titration · Mean difference: 1.2 · 95% CI 0.1 to 2.3Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference: -1.8 · 95% CI -2.7 to -0.9Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 + ASA vs BG00012 Slow Titration · Mean difference: 0.6 · 95% CI -0.4 to 1.6Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference: -1.9 · 95% CI -2.8 to -1.0Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 + ASA vs BG00012 Slow Titration · Mean difference: 1.2 · 95% CI 0.2 to 2.2Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
PrimaryWorst Severity Scores of Overall Flushing During Weeks 5 to 8 of Treatment (Combined), as Assessed by MFSS

Worst severity of participant-reported flushing events during Weeks 1-4 of treatment combined, recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin.This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects).

Time frame:
Week 5 to Week 8
Reported as:
Mean · units on a scale
Worst Severity Scores of Overall Flushing During Weeks 5 to 8 of Treatment (Combined), as Assessed by MFSS
units on a scalePlaceboBG00012BG00012 + ASABG00012 Slow Titration
Overall flushing0.9 ± 1.673.8 ± 2.483.3 ± 2.783.1 ± 2.26
Redness0.4 ± 1.143.6 ± 2.732.9 ± 2.672.9 ± 2.30
Warmth0.8 ± 1.793.9 ± 2.533.1 ± 2.502.9 ± 2.15
Tingling0.3 ± 0.823.3 ± 2.502.3 ± 2.362.2 ± 1.96
Itching0.7 ± 1.583.1 ± 2.712.3 ± 2.521.8 ± 2.04
Statistical analysis
  • BG00012 vs BG00012 + ASA · Mean difference: -0.5 · 95% CI -1.7 to 0.8Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference: -0.7 · 95% CI -1.8 to 0.4Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference: -0.7 · 95% CI -2.0 to 0.6Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference: -0.7 · 95% CI -1.9 to 0.5Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference: -0.8 · 95% CI -2.0 to 0.4Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference: -0.9 · 95% CI -2.1 to 0.2Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference: -1.0 · 95% CI -2.2 to 0.1Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference: -1.1 · 95% CI -2.2 to -0.0Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference: -0.8 · 95% CI -2.1 to 0.4Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference: -1.3 · 95% CI -2.4 to -0.1Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
PrimaryPercentage of Participants Reporting Overall Flushing Events During the Overall Treatment Period, as Assessed by the Modified Global Flushing Severity Scale (MGFSS)

Participant-reported flushing events during the overall treatment period, recorded on the hand-held participant reporting device (eDiary) as assessed by MGFSS. The MGFSS measures the side effects related to flushing during the past 24 hours. Flushing means redness, warmth, tingling or itching of the skin. Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). Day 1 data are not included in the analysis because MGFSS question refers to events reported in the 24 hours after the first dose on Day 1.

Time frame:
Day 2 to Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Overall Flushing Events During the Overall Treatment Period, as Assessed by the Modified Global Flushing Severity Scale (MGFSS)
percentage of participantsPlaceboBG00012BG00012 + ASABG00012 Slow Titration
Percentage of Participants Reporting Overall Flushing Events During the Overall Treatment Period, as Assessed by the Modified Global Flushing Severity Scale (MGFSS)43867493
Statistical analysis
  • BG00012 vs BG00012 + ASA · Difference in percentage: -12 · 95% CI -32.2 to 9.5Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: 7 · 95% CI -14.1 to 27.8Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
PrimaryPercentage of Participants Reporting Overall Flushing Events During Weeks 1 to 4 of Treatment (Combined), as Assessed by MGFSS

Participant-reported flushing events during Weeks 1 to 4 of treatment (combined), recorded on the hand-held participant reporting device (eDiary) as assessed by MGFSS. The MGFSS measures the side effects related to flushing during the past 24 hours. Flushing means redness, warmth, tingling or itching of the skin. Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). Day 1 data are not included in the analysis because MGFSS question refers to events reported in the 24 hours after the first dose on Day 1.

Time frame:
Day 2 to Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Overall Flushing Events During Weeks 1 to 4 of Treatment (Combined), as Assessed by MGFSS
percentage of participantsPlaceboBG00012BG00012 + ASABG00012 Slow Titration
Percentage of Participants Reporting Overall Flushing Events During Weeks 1 to 4 of Treatment (Combined), as Assessed by MGFSS41846290
Statistical analysis
  • BG00012 vs BG00012 + ASA · Difference in percentage: -22 · 95% CI -41.0 to 0.1Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: 7 · 95% CI -14.1 to 27.8Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
PrimaryPercentage of Participants Reporting Overall Flushing Events During Weeks 5 to 8 of Treatment (Combined), as Assessed by MGFSS

Participant-reported flushing events during Weeks 5 to 8 of treatment (combined), recorded on the hand-held participant reporting device (eDiary) as assessed by MGFSS. The MGFSS measures the side effects related to flushing during the past 24 hours. Flushing means redness, warmth, tingling or itching of the skin. Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). Day 1 data are not included in the analysis because MGFSS question refers to last 24 hours flushing score.

Time frame:
Week 5 to Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Overall Flushing Events During Weeks 5 to 8 of Treatment (Combined), as Assessed by MGFSS
percentage of participantsPlaceboBG00012BG00012 + ASABG00012 Slow Titration
Percentage of Participants Reporting Overall Flushing Events During Weeks 5 to 8 of Treatment (Combined), as Assessed by MGFSS24866785
Statistical analysis
  • BG00012 vs BG00012 + ASA · Difference in percentage: -20 · 95% CI -40.6 to 3.8Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: -2 · 95% CI -24.7 to 21.7Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
PrimaryPercentage of Participants Reporting Gastrointestinal (GI) Events During the Overall Treatment Period, as Assessed by the Modified Acute Gastrointestinal Scale (MAGISS)

The MAGISS is a participant-reported questionnaire about side effects of the gastrointestinal system following drug administration, and is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. A participant was considered having overall GI side effect if he/she had a score of \>=1 for at least one of the GI side effects including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating and flatulence.

Time frame:
Day 1 to Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Gastrointestinal (GI) Events During the Overall Treatment Period, as Assessed by the Modified Acute Gastrointestinal Scale (MAGISS)
percentage of participantsPlaceboBG00012BG00012 + ASABG00012 Slow Titration
Percentage of Participants Reporting Gastrointestinal (GI) Events During the Overall Treatment Period, as Assessed by the Modified Acute Gastrointestinal Scale (MAGISS)73818186
Statistical analysis
  • BG00012 vs BG00012 + ASA · Difference in percentage: 0 · 95% CI -22.0 to 22.0Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: 4 · 95% CI -16.4 to 25.5Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
PrimaryPercentage of Participants Reporting GI Events During Weeks 1 to 4 of Treatment (Combined), as Assessed by MAGISS

The MAGISS is a participant-reported questionnaire about side effects of the gastrointestinal system following drug administration, and is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. A participant was considered having overall GI side effect if he/she had a score of \>=1 for at least one of the GI side effects including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating and flatulence.

Time frame:
Day 1 to Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Reporting GI Events During Weeks 1 to 4 of Treatment (Combined), as Assessed by MAGISS
percentage of participantsPlaceboBG00012BG00012 + ASABG00012 Slow Titration
Percentage of Participants Reporting GI Events During Weeks 1 to 4 of Treatment (Combined), as Assessed by MAGISS66817979
Statistical analysis
  • BG00012 vs BG00012 + ASA · Difference in percentage: -2 · 95% CI -24.2 to 19.7Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: -3 · 95% CI -23.3 to 18.7Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
PrimaryPercentage of Participants Reporting GI Events During Weeks 5 to 8 of Treatment (Combined), as Assessed by MAGISS

The MAGISS is a participant-reported questionnaire about side effects of the gastrointestinal system following drug administration, and is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. A participant was considered having overall GI side effect if he/she had a score of \>=1 for at least one of the GI side effects including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating and flatulence.

Time frame:
Week 5 to Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Reporting GI Events During Weeks 5 to 8 of Treatment (Combined), as Assessed by MAGISS
percentage of participantsPlaceboBG00012BG00012 + ASABG00012 Slow Titration
Percentage of Participants Reporting GI Events During Weeks 5 to 8 of Treatment (Combined), as Assessed by MAGISS41595361
Statistical analysis
  • BG00012 vs BG00012 + ASA · Difference in percentage: -7 · 95% CI -29.4 to 17.1Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: 1 · 95% CI -22.1 to 24.5Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
PrimaryWorst Severity Scores of Acute GI Events During Weeks 1 to 4 of Treatment (Combined), as Assessed by MAGISS

Severity of GI-related events using the MAGISS to measure GI symptoms (nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, flatulence), based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms.

Time frame:
Day 1 to Week 4
Reported as:
Mean · units on a scale
Worst Severity Scores of Acute GI Events During Weeks 1 to 4 of Treatment (Combined), as Assessed by MAGISS
units on a scalePlaceboBG00012BG00012 + ASABG00012 Slow Titration
Nausea0.7 ± 1.591.6 ± 2.411.6 ± 2.541.5 ± 2.09
Diarrhea1.0 ± 1.971.8 ± 2.471.5 ± 2.761.0 ± 1.67
Upper abdominal pain0.8 ± 1.381.1 ± 2.161.7 ± 2.711.4 ± 2.47
Lower abdominal pain0.5 ± 1.211.4 ± 2.141.3 ± 2.321.2 ± 2.12
Vomiting0.2 ± 0.750.3 ± 1.280.3 ± 1.630.2 ± 1.10
Indigestion0.7 ± 1.290.9 ± 1.830.6 ± 1.260.9 ± 1.97
Constipation0.4 ± 1.450.9 ± 2.230.6 ± 1.450.9 ± 1.85
Bloating0.5 ± 1.171.1 ± 1.961.3 ± 2.081.0 ± 1.88
Flatulence1.3 ± 1.731.3 ± 2.031.4 ± 1.761.6 ± 2.20
Statistical analysis
  • BG00012 vs BG00012 + ASA · Mean difference (final values): 0.0 · 95% CI -1.1 to 1.1Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -0.1 · 95% CI -1.1 to 0.9Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): -0.3 · 95% CI -1.4 to 0.8Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -0.8 · 95% CI -1.7 to 0.1Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): 0.6 · 95% CI -0.5 to 1.6Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (net): 0.3 · 95% CI -0.7 to 1.3Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): -0.0 · 95% CI -1.0 to 0.9Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -0.2 · 95% CI -1.1 to 0.8Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): 0.0 · 95% CI -0.6 to 0.7Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -0.0 · 95% CI -0.6 to 0.5Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): -0.3 · 95% CI -1.0 to 0.3Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): 0.0 · 95% CI -0.8 to 0.8Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): -0.2 · 95% CI -1.0 to 0.6Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): 0.0 · 95% CI -0.8 to 0.9Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Difference in percentage: 0.2 · 95% CI -0.7 to 1.1
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -0.1 · 95% CI -0.9 to 0.7Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): 0.0 · 95% CI -0.8 to 0.9Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (net): 0.2 · 95% CI -0.7 to 1.1Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
PrimaryWorst Severity Scores of Acute GI Events During Weeks 5 to 8 of Treatment (Combined), as Assessed by MAGISS

Severity of GI-related events using the MAGISS to measure GI symptoms (nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, flatulence), based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms.

Time frame:
Week 5 to Week 8
Reported as:
Mean · units on a scale
Worst Severity Scores of Acute GI Events During Weeks 5 to 8 of Treatment (Combined), as Assessed by MAGISS
units on a scalePlaceboBG00012BG00012 + ASABG00012 Slow Titration
Nausea0.4 ± 1.510.9 ± 1.790.8 ± 1.940.9 ± 1.65
Diarrhea1.0 ± 2.011.4 ± 2.290.8 ± 2.130.7 ± 1.42
Upper abdominal pain0.6 ± 1.690.5 ± 1.500.4 ± 1.210.6 ± 1.56
Lower abdominal pain0.6 ± 1.480.4 ± 1.420.5 ± 1.380.9 ± 1.72
Vomiting0.2 ± 1.410.1 ± 0.820.1 ± 0.830.0 ± 0.00
Indigestion0.4 ± 1.260.5 ± 1.320.5 ± 1.380.4 ± 1.06
Constipation0.4 ± 1.200.1 ± 0.590.6 ± 1.630.3 ± 1.05
Bloating0.5 ± 1.230.7 ± 1.610.7 ± 1.550.8 ± 1.52
Flatulence0.8 ± 1.651.2 ± 2.040.4 ± 1.080.9 ± 1.54
Statistical analysis
  • BG00012 vs BG00012 + ASA · Mean difference (final values): -0.1 · 95% CI -1.0 to 0.8Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -0.0 · 95% CI -0.8 to 0.8Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): -0.7 · 95% CI -1.7 to 0.4Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -0.7 · 95% CI -1.7 to 0.2Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): -0.1 · 95% CI -0.7 to 0.6Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (net): 0.1 · 95% CI -0.7 to 0.8Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): 0.1 · 95% CI -0.6 to 0.7Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): 0.5 · 95% CI -0.2 to 1.3Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): 0.0 · 95% CI -0.4 to 0.4Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -0.1 · 95% CI -0.4 to 0.2Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): -0.0 · 95% CI -0.6 to 0.6Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -0.1 · 95% CI -0.7 to 0.5Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): 0.4 · 95% CI -0.1 to 1.0Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): 0.2 · 95% CI -0.2 to 0.6Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): -0.1 · 95% CI -0.8 to 0.7Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (net): 0.0 · 95% CI -0.7 to 0.8Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): -0.8 · 95% CI -1.6 to -0.0Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -0.3 · 95% CI -1.2 to 0.5Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
PrimaryPercentage of Participants Reporting GI Events During the Overall Treatment Period, as Assessed by the Modified Overall Gastrointestinal Symptom Scale (MOGISS)

The MOGISS is a questionnaire about overall side effects related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. Participants were to answer the questions at the same time each day, before the morning drug administration.

Time frame:
Day 1 to Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Reporting GI Events During the Overall Treatment Period, as Assessed by the Modified Overall Gastrointestinal Symptom Scale (MOGISS)
percentage of participantsPlaceboBG00012BG00012 + ASABG00012 Slow Titration
Percentage of Participants Reporting GI Events During the Overall Treatment Period, as Assessed by the Modified Overall Gastrointestinal Symptom Scale (MOGISS)59707979
Statistical analysis
  • BG00012 vs BG00012 + ASA · Difference in percentage: 9 · 95% CI -11.8 to 30.0Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: 9 · 95% CI -11.8 to 30.0Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
PrimaryPercentage of Participants Reporting GI Events During Weeks 1 to 4 (Combined), as Assessed by the Modified Overall Gastrointestinal Symptom Scale (MOGISS)

The MOGISS is a questionnaire about overall side effects related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. Participants were to answer the questions at the same time each day, before the morning drug administration.

Time frame:
Week 1 to Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Reporting GI Events During Weeks 1 to 4 (Combined), as Assessed by the Modified Overall Gastrointestinal Symptom Scale (MOGISS)
percentage of participantsPlaceboBG00012BG00012 + ASABG00012 Slow Titration
Percentage of Participants Reporting GI Events During Weeks 1 to 4 (Combined), as Assessed by the Modified Overall Gastrointestinal Symptom Scale (MOGISS)57656771
Statistical analysis
  • BG00012 vs BG00012 + ASA · Difference in percentage: 2 · 95% CI -18.8 to 23.3Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: 6 · 95% CI -14.1 to 27.8Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
PrimaryPercentage of Participants Reporting GI Events During Weeks 5 to 8 (Combined), as Assessed by the Modified Overall Gastrointestinal Symptom Scale (MOGISS)

The MOGISS is a questionnaire about overall side effects related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. Participants were to answer the questions at the same time each day, before the morning drug administration.

Time frame:
Week 5 to Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Reporting GI Events During Weeks 5 to 8 (Combined), as Assessed by the Modified Overall Gastrointestinal Symptom Scale (MOGISS)
percentage of participantsPlaceboBG00012BG00012 + ASABG00012 Slow Titration
Percentage of Participants Reporting GI Events During Weeks 5 to 8 (Combined), as Assessed by the Modified Overall Gastrointestinal Symptom Scale (MOGISS)34595058
Statistical analysis
  • BG00012 vs BG00012 + ASA · Difference in percentage: -9 · 95% CI -32.1 to 14.3Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Difference in percentage: -2 · 95% CI -25.0 to 21.7Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) or Serious AEs (SAEs)

AE: any untoward medical occurrence that does not necessarily have a causal relationship with treatment. SAE: any untoward medical occurrence that at any dose: results in death; in the view of the Investigator, places the subject at immediate risk of death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, may jeopardize the subject or may require intervention to prevent one of the other outcomes. An AE was considered treatment-emergent if it occurred after the start of study treatment or was present prior to the start of study treatment but subsequently worsened.

Time frame:
Day 1 up to end of Safety Follow-up (9 weeks)
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious AEs (SAEs)
participantsPlaceboBG00012BG00012 + ASABG00012 Slow Titration
Any event24242626
Moderate or severe event10131211
Severe event0441
Related event8171618
Serious event0100
Discontinuation of treatment due to an event2463
Withdrawal from study due to an event2463
SecondaryClinical Laboratory Shifts From Baseline in Reported Values: Hematology

Number of participants with clinical laboratory shifts from baseline in hematology values. Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. abs=absolute

Time frame:
Day 1 to Week 8
Reported as:
Number · participants
Clinical Laboratory Shifts From Baseline in Reported Values: Hematology
participantsPlaceboBG00012BG00012 + ASABG00012 Slow Titration
White blood cells: shift to low; n=43, 43, 43, 410200
White blood cells: shift to high; n=44, 43, 43, 420010
Neutrophils abs: shift to low; n=42, 42, 42, 413622
Neutrophils abs: shift to high; n=44, 43, 43, 420001
Lymphocytes abs: shift to low; n=43, 43, 43, 411523
Lymphocytes abs: shift to high; n=44, 43, 42, 420000
Monocytes abs: shift to low; n=44, 43, 43, 420000
Monocytes abs: shift to high; n=44, 43, 43, 420000
Eosinophils abs: shift to low; n=44, 43, 43, 420000
Eosinophils abs: shift to high; n=44, 43, 43, 420566
Basophils abs: shift to high; n=44, 43, 43, 420110
Red blood cells: shift to low; n=44, 43, 43, 400200
Red blood cells: shift to high; n=44, 43, 43, 420000
Hemoglobin: shift to low; n=43, 41, 43, 421310
Hemoglobin: shift to high; n=44, 43, 43, 420000
Hematocrit: shift to low; n=44, 43, 43, 420200
Hematocrit: shift to high; n=43, 43, 43, 420001
Platelets: shift to low; n=44, 43, 43, 420000
Platelets: shift to high; n=44, 41, 43, 420011
SecondaryClinical Laboratory Shifts From Baseline in Reported Values: Blood Chemistry

Number of participants with clinical laboratory shifts from baseline in blood chemistry values. Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. ALP=alkaline phosphatase, ALT=alanine aminotransferase, AST=aspartate aminotransferase, GGT=gamma-glutamyl transferase, LDH=lactate dehydrogenase, BUN=blood urea nitrogen.

Time frame:
Day 1 to Week 8
Reported as:
Number · participants
Clinical Laboratory Shifts From Baseline in Reported Values: Blood Chemistry
participantsPlaceboBG00012BG00012 + ASABG00012 Slow Titration
ALP: shift to high; n=44, 42, 43, 420000
ALT: shift to high; n=44, 42, 43, 421252
AST: shift to high; n=44, 43, 43, 412341
GGT: shift to high; n=44, 41, 43, 420020
LDH: shift to low; n=44, 43, 43, 420000
LDH: shift to high; n=44, 43, 43, 420010
Total bilirubin: shift to high; n=44, 42, 42, 401101
BUN: shift to low; n=44, 43, 43, 420000
BUN: shift to high; n=44, 43, 41, 421011
Creatinine: shift to low; n=44, 43, 43, 420100
Creatinine: shift to high; n=44, 43, 43, 420000
Uric Acid: shift to low; n=44, 43, 43, 420000
Uric Acid: shift to high; n=44, 43, 43, 420000
Sodium: shift to low; n=44, 43, 43, 421000
Sodium: shift to high; n=44, 43, 43, 420010
Potassium: shift to low: n=44, 43, 43, 420000
Potassium: shift to high: n=44, 42, 42, 411110
Chloride: shift to low; n=44, 43, 43, 421000
Chloride: shift to high; n=44, 43, 43, 420000
Bicarbonate: shift to low; n=44, 43, 43, 421110
Bicarbonate: shift to high; n=44, 43, 43, 420000
Calcium: shift to low; n=44, 42, 43, 420010
Calcium: shift to high; n=44, 43, 43, 420000
Glucose: shift to low; n=43, 43, 41, 413112
Glucose: shift to high; n=44, 43, 43, 421000
Magnesium: shift to low; n=44, 43, 43, 421001
Magnesium: shift to high; n=44, 43, 43, 420000
Phosphorus: shift to low; n=44, 43, 43, 410100
Phosphorus: shift to high; n=44, 43, 43, 420001
Albumin: shift to low; n=44, 43, 43, 420000
Albumin: shift to high; n=44, 43, 43, 420000
Direct bilirubin: shift to high; n=44, 43, 43, 400000
Total protein: shift to low; n=44, 41, 43, 410010
Total protein: shift to high; n=44, 43, 43, 420000
SecondaryClinical Laboratory Shifts From Baseline in Reported Values: Urinalysis

Number of participants with clinical laboratory shifts from baseline in urinalysis values.Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. Shift to positive includes negative to positive and unknown to positive. RBC=red blood cells, WBC=white blood cells.

Time frame:
Day 1 to Week 8
Reported as:
Number · participants
Clinical Laboratory Shifts From Baseline in Reported Values: Urinalysis
participantsPlaceboBG00012BG00012 + ASABG00012 Slow Titration
Specific gravity: shift to low; n=44, 43, 43, 420000
Specific gravity: shift to high; n=44, 42, 43, 420020
pH: shift to low; n=44, 43, 43, 420000
pH: shift to high; n=44, 43, 43, 420000
Blood: shift to positive; n=42, 39, 39, 423612
Color: shift to positive; n=41, 43, 41, 392145
Glucose: shift to positive; n=44, 43, 43, 410210
Ketones: shift to positive; n=44, 43, 43, 421796
Protein: shift to positive; n=44, 41, 43, 410111
Microscopic RBC; n=44, 40, 40, 413412
Microscopic WBC; n=43, 40, 41, 424933
SecondaryNumber of Participants With Abnormalities in Vital Signs

↑=increase; ↓=decrease; BL=baseline; bpm=beats per minute; SBP=systolic blood pressure; DBP=diastolic blood pressure; b/m=breaths per minute

Time frame:
Day 1 to Week 8
Reported as:
Number · participants
Number of Participants With Abnormalities in Vital Signs
participantsPlaceboBG00012BG00012 + ASABG00012 Slow Titration
Temperature >38°C + ↑ from BL of ≥1°C0000
Pulse >120 bpm or ↑ from BL of >20 bpm8102017
Pulse <50 bpm or ↓ from BL of >20 bpm11434
SBP >180 mm Hg or ↑ from BL of >40 mm Hg1000
SBP <90 mm Hg or ↓ from BL of >30 mm Hg1211
DBP >105 mm Hg or ↑ from BL of >30 mm Hg0000
DBP <50 mm Hg or ↓ from BL of >20 mm Hg1301
Respiration rate >25 b/m or ↑ from BL of ≥50%1233
Respiration rate 10 b/m or ↓ from BL of ≥50%0000
SecondaryNumber of Participants With Shifts From Baseline in Electrocardiogram (ECG) Results

Shift to 'abnormal, not adverse event' includes unknown or normal to 'abnormal, not adverse event.' Shift to 'abnormal, adverse event' includes unknown or normal to 'abnormal, adverse event.'

Time frame:
Day 1 to Week 8
Reported as:
Number · participants
Number of Participants With Shifts From Baseline in Electrocardiogram (ECG) Results
participantsPlaceboBG00012BG00012 + ASABG00012 Slow Titration
Shift to abnormal, not adverse event2324
Shift to abnormal, adverse event0000
SecondaryDuration of Flushing Events During the Overall Treatment Period, Based on MFSS

For participants with more than 1 flushing episode during a visit interval, the average duration for the visit interval was used. The average duration is calculated as: the total duration of all flushing episodes / the total number of flushing episodes.

Time frame:
Day 1 to Week 8
Reported as:
Mean · minutes
Duration of Flushing Events During the Overall Treatment Period, Based on MFSS
minutesPlaceboBG00012BG00012 + ASABG00012 Slow Titration
Duration of Flushing Events During the Overall Treatment Period, Based on MFSS98.4 ± 92.0463.2 ± 34.5569.8 ± 78.0968.9 ± 52.82
Statistical analysis
  • BG00012 vs BG00012 + ASA · Mean difference (final values): 6.6 · 95% CI -20.9 to 34.1Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): 5.8 · 95% CI -14.2 to 25.7Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
SecondaryDuration of Flushing Events During the Weeks 1 to 4 (Combined), Based on MFSS

For participants with more than 1 flushing episode during a visit interval, the average duration for the visit interval was used. The average duration is calculated as: the total duration of all flushing episodes / the total number of flushing episodes.

Time frame:
Week 1 to Week 4
Reported as:
Mean · minutes
Duration of Flushing Events During the Weeks 1 to 4 (Combined), Based on MFSS
minutesPlaceboBG00012BG00012 + ASABG00012 Slow Titration
Duration of Flushing Events During the Weeks 1 to 4 (Combined), Based on MFSS117.6 ± 143.9067.6 ± 43.8389.8 ± 140.6769.2 ± 53.00
Statistical analysis
  • BG00012 vs BG00012 + ASA · Mean difference (final values): 22.2 · 95% CI -26.5 to 70.9Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): 1.6 · 95% CI -20.5 to 23.6Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
SecondaryDuration of Flushing Events During the Weeks 5 to 8 (Combined), Based on MFSS

For participants with more than 1 flushing episode during a visit interval, the average duration for the visit interval was used. The average duration is calculated as: the total duration of all flushing episodes / the total number of flushing episodes.

Time frame:
Week 5 to Week 8
Reported as:
Mean · minutes
Duration of Flushing Events During the Weeks 5 to 8 (Combined), Based on MFSS
minutesPlaceboBG00012BG00012 + ASABG00012 Slow Titration
Duration of Flushing Events During the Weeks 5 to 8 (Combined), Based on MFSS113.2 ± 160.8255.7 ± 32.3773.2 ± 66.3456.0 ± 35.79
Statistical analysis
  • BG00012 vs BG00012 + ASA · Mean difference (final values): 17.5 · 95% CI -9.2 to 44.2Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): 0.4 · 95% CI -17.2 to 18.0Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
SecondaryDuration of Acute GI Episodes During the Overall Treatment Period, Based on MAGISS

Duration is calculated as follows: \[(GI side effect) end date/time - (GI side effect) start date/time\]/3600. For GI side effects with no end date, the end date is imputed using the last diary date/time. For subjects with more than 1 GI episode during a visit interval, the average duration for the study visit interval is used. The average duration is calculated as the total duration of the GI side effect / the total number of GI side effects.

Time frame:
Day 1 to Week 8
Reported as:
Mean · hours
Duration of Acute GI Episodes During the Overall Treatment Period, Based on MAGISS
hoursPlaceboBG00012BG00012 + ASABG00012 Slow Titration
Nausea; n=12, 21, 21, 229.74 ± 17.0087.05 ± 10.49810.01 ± 18.2832.98 ± 3.247
Diarrhea; n=20, 20 17, 155.57 ± 10.0372.92 ± 3.32914.66 ± 32.6864.97 ± 9.687
Upper abdominal pain; n=17, 14, 19, 1919.08 ± 46.8736.67 ± 16.91615.88 ± 25.3073.83 ± 5.712
Lower abdominal pain; n=12, 19, 17, 166.65 ± 5.30713.93 ± 26.85010.84 ± 16.3127.75 ± 10.456
Vomiting; n=3, 3, 3, 25.87 ± 5.03310.08 ± 8.7551.88 ± 2.7170.75 ± 0.707
Indigestion; n=12, 13, 12, 124.76 ± 8.20316.49 ± 28.8653.80 ± 2.5434.91 ± 8.263
Constipation; n=6, 8, 13, 1120.49 ± 12.04028.20 ± 35.42514.26 ± 9.78320.90 ± 18.060
Bloating; n=14, 14, 21, 129.50 ± 9.06616.91 ± 27.1289.68 ± 10.10877.24 ± 125.961
Flatulence; n=23, 20, 22, 2016.41 ± 44.1499.06 ± 9.62668.93 ± 290.24863.84 ± 180.597
Statistical analysis
  • BG00012 vs BG00012 + ASA · Mean difference (final values): 2.96 · 95% CI -6.34 to 12.26Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -4.07 · 95% CI -8.81 to 0.67Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): 11.74 · 95% CI -3.15 to 26.63Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): 2.05 · 95% CI -2.67 to 6.77Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): 9.21 · 95% CI -6.72 to 25.14Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -2.84 · 95% CI -11.31 to 5.63Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): -3.09 · 95% CI -18.36 to 12.19Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -6.18 · 95% CI -20.71 to 8.35Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): -8.21 · 95% CI -22.90 to 6.49Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -9.33 · 95% CI -30.13 to 11.47Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): -12.69 · 95% CI -30.02 to 4.63Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -11.58 · 95% CI -29.48 to 6.32Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): -13.93 · 95% CI -35.44 to 7.57Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -7.29 · 95% CI -33.39 to 18.81Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): -7.24 · 95% CI -20.40 to 5.93Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): 60.33 · 95% CI -10.78 to 131.4Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): 59.87 · 95% CI -71.51 to 191.2Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): 54.78 · 95% CI -27.09 to 136.6Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
SecondaryDuration of Acute GI Episodes During Weeks 1 to 4 (Combined), Based on MAGISS

Duration is calculated as follows: \[(GI side effect) end date/time - (GI side effect) start date/time\]/3600. For GI side effects with no end date, the end date is imputed using the last diary date/time. For subjects with more than 1 GI episode during a visit interval, the average duration for the study visit interval is used. The average duration is calculated as the total duration of the GI side effect / the total number of GI side effects.

Time frame:
Week 1 to Week 4
Reported as:
Mean · hours
Duration of Acute GI Episodes During Weeks 1 to 4 (Combined), Based on MAGISS
hoursPlaceboBG00012BG00012 + ASABG00012 Slow Titration
Nausea; n=10, 18, 18, 2010.47 ± 18.6787.23 ± 10.91611.18 ± 19.5682.86 ± 3.359
Diarrhea; n=13, 20, 14, 145.20 ± 11.3092.53 ± 3.01316.04 ± 35.9454.97 ± 10.074
Upper abdominal pain; n=14, 14, 17, 1521.37 ± 51.6206.81 ± 16.87617.65 ± 26.2944.31 ± 6.350
Lower abdominal pain; n=9, 18, 14, 135.40 ± 4.65814.20 ± 27.63712.51 ± 17.6216.30 ± 6.080
Vomiting; n=2, 2, 2, 24.31 ± 5.9995.63 ± 5.8342.53 ± 3.5000.75 ± 0.707
Indigestion; n=11, 11, 9, 115.08 ± 8.55229.00 ± 48.4163.93 ± 2.8735.05 ± 8.665
Constipation; n=4, 8, 11, 1117.05 ± 7.45227.61 ± 35.17715.12 ± 7.76121.28 ± 19.298
Bloating; n=9, 14, 19, 116.70 ± 6.79213.81 ± 25.32111.07 ± 10.63195.69 ± 186.884
Flatulence; n=21, 17, 22, 1912.83 ± 27.9489.34 ± 12.94635.86 ± 134.74861.13 ± 168.572
Statistical analysis
  • BG00012 vs BG00012 + ASA · Mean difference (final values): 3.95 · 95% CI -6.79 to 14.68Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -4.37 · 95% CI -9.57 to 0.83Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): 13.51 · 95% CI -2.84 to 29.86Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): 2.44 · 95% CI -2.41 to 7.29Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): 10.84 · 95% CI -5.81 to 27.50Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -2.50 · 95% CI -12.08 to 7.09Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): -1.69 · 95% CI -19.03 to 15.64Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -7.91 · 95% CI -23.93 to 8.11Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): -3.10 · 95% CI -23.80 to 17.60Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -4.88 · 95% CI -22.75 to 13.00Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): -25.08 · 95% CI -59.20 to 9.05Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -23.95 · 95% CI -54.89 to 6.98Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): -12.49 · 95% CI -35.38 to 10.39Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -6.33 · 95% CI -32.79 to 20.13Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): -2.73 · 95% CI -15.87 to 10.41Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): 81.89 · 95% CI -22.04 to 185.8Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): 26.52 · 95% CI -40.13 to 93.18Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): 51.78 · 95% CI -31.65 to 135.2Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
SecondaryDuration of Acute GI Episodes During Weeks 5 to 8 (Combined), Based on MAGISS

Duration is calculated as follows: \[(GI side effect) end date/time - (GI side effect) start date/time\]/3600. For GI side effects with no end date, the end date is imputed using the last diary date/time. For subjects with more than 1 GI episode during a visit interval, the average duration for the study visit interval is used. The average duration is calculated as the total duration of the GI side effect / the total number of GI side effects.

Time frame:
Week 5 to Week 8
Reported as:
Mean · hours
Duration of Acute GI Episodes During Weeks 5 to 8 (Combined), Based on MAGISS
hoursPlaceboBG00012BG00012 + ASABG00012 Slow Titration
Nausea; n=4, 9, 6, 93.96 ± 3.6684.34 ± 6.2562.66 ± 1.3902.34 ± 1.904
Diarrhea; n=12, 13, 6, 84.50 ± 6.3896.62 ± 12.7827.05 ± 8.0022.14 ± 2.007
Upper abdominal pain; n=6, 5, 5, 55.29 ± 5.7851.12 ± 0.9651.86 ± 1.4911.73 ± 1.440
Lower abdominal pain; n=7, 5, 5, 96.63 ± 7.7393.98 ± 3.5162.84 ± 1.47722.54 ± 61.180
Vomiting; n=1, 1, 1, 09.00 ± NA19.00 ± NA0.58 ± NANA ± NA
Indigestion; n=6, 7, 7, 52.43 ± 1.5692.57 ± 2.5865.02 ± 6.9441.63 ± 1.101
Constipation; n=5, 2, 4, 423.35 ± 17.11015.47 ± 21.14321.30 ± 23.18118.24 ± 8.644
Bloating; n=7, 8, 7, 812.49 ± 10.59518.52 ± 25.6824.16 ± 3.01885.64 ± 115.872
Flatulence; n=9, 13, 7, 1044.67 ± 112.4267.21 ± 10.051105.86 ± 275.12518.48 ± 26.347
Statistical analysis
  • BG00012 vs BG00012 + ASA · Mean difference (final values): -1.68 · 95% CI -7.35 to 3.99Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -2.00 · 95% CI -6.62 to 2.62Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): 0.43 · 95% CI -11.64 to 12.49Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -4.48 · 95% CI -14.11 to 5.14
  • BG00012 vs BG00012 + ASA · Mean difference (final values): 0.74 · 95% CI -1.10 to 2.57Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): 0.61 · 95% CI -1.17 to 2.40Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): -1.14 · 95% CI -5.08 to 2.79Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): 18.56 · 95% CI -42.19 to 79.32Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): 2.46 · 95% CI -3.65 to 8.56Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): -0.94 · 95% CI -3.71 to 1.83Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): 5.83 · 95% CI -48.73 to 60.38Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): 2.76 · 95% CI -28.38 to 33.91Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): -14.36 · 95% CI -35.56 to 6.83Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): 67.12 · 95% CI -22.88 to 157.1Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 + ASA · Mean difference (final values): 98.65 · 95% CI -58.01 to 255.3Reference arm is BG00012 240 mg BID; negative values means reduced side effect.
  • BG00012 vs BG00012 Slow Titration · Mean difference (final values): 11.27 · 95% CI -5.22 to 27.76Reference arm is BG00012 240 mg BID; negative values means reduced side effect.

Adverse events

Collected over AEs: from the administration of the first dose of study treatment to the Safety Follow-up (approximately 9 weeks). SAEs: from signing of informed consent to the Safety Follow-up (up to approximately 13 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/44 (0%)5/44 (11.4%)
BG00012—1/43 (2.3%)12/43 (27.9%)
BG00012 + ASA—0/43 (0%)15/43 (34.9%)
BG00012 Slow Titration—0/42 (0%)12/42 (28.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboBG00012BG00012 + ASABG00012 Slow Titration
Ovarian germ cell teratoma stage INeoplasms benign, malignant and unspecified (incl cysts and polyps)0/441/430/430/42
Most frequent other events
Most frequent other events
EventPlaceboBG00012BG00012 + ASABG00012 Slow Titration
HeadacheNervous system disorders4/449/432/439/42
Upper respiratory tract infectionInfections and infestations1/443/437/431/42
DiarrhoeaGastrointestinal disorders0/442/435/430/42
EosinophiliaBlood and lymphatic system disorders0/441/433/432/42
Abdominal painGastrointestinal disorders0/440/433/430/42
VomitingGastrointestinal disorders0/442/433/430/42

Baseline characteristics

All randomized and treated participants

Age, Continuous
Age, Continuous(years)PlaceboBG00012BG00012 + ASABG00012 Slow TitrationTotal
Mean35.5 ± 8.7839.0 ± 9.6138.1 ± 10.2936.2 ± 9.3337.2 ± 9.54
Age, Customized
Age, Customized(participants)PlaceboBG00012BG00012 + ASABG00012 Slow TitrationTotal
25 to 34 years2219172179
35 to 44 years137131043
45 to 55 years917131150
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBG00012BG00012 + ASABG00012 Slow TitrationTotal
Female1421172072
Male30222622100
08

Study locations

1 site
  • Research Site
    St Paul, Minnesota, United States
09

References and documents

Publications

  • O'Gorman J, Russell HK, Li J, Phillips G, Kurukulasuriya NC, Viglietta V. Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate. Clin Ther. 2015 Jul 1;37(7):1402-1419.e5. doi: 10.1016/j.clinthera.2015.03.028. Epub 2015 May 19. PubMed 25999183 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2012
First posted
Apr 2, 2012
Start
Apr 2012
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Results first posted
Jun 13, 2016
Last update
Jun 13, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01568112
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Apr 2, 2012
Start date
Apr 2012
Primary completion
Oct 2012
Completion
Oct 2012
Results posted
Jun 13, 2016
Last update
Jun 13, 2016

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimethyl Fumarate

Start the discussion